Five of the Latest Pemphigoid Disease Clinical Trials Completed with Results

It is essential for clinicians to remain informed about emerging clinical trial opportunities and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life. Today, we have a selection of clinical trials on pemphigoid disease, the majority of which focus on bullous pemphigoid, with the sole exception being a trial that includes mucous membrane pemphigoid as an oral inflammatory ulcerative disease.

The following trials are arranged by start date, with dates ranging from 2016 through 2022. Results for every trial are viewable on their respective source pages.

Quick View Table of Pemphigoid Disease Clinical Trials

Featured Clinical Trials on Pemphigoid Diseases

A Phase 2/​3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)

• Sponsor: Argenx
• Goal: This study intends to demonstrate that efgartigimod is an effective and safe treatment for BP, providing participants with control of disease activity and eventually remission while reducing their cumulative exposure to OCS.
• Interventions: Efgartigimod PH20 SC, placebo, prednisone
• Primary Outcome Measure: Number of participants with CRoff at week 36.
• Time Frame: At week 36.
• Study Details
• Source

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (LIBERTY-BP)

• Sponsor: Regeneron Pharmaceuticals
• Goal: The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid.
• Interventions: Dupilumab, matching placebo, oral corticosteroids
• Primary Outcome Measure: Percent of participants achieving sustained remission at week 36.
• Time Frame: At week 36.
• Study Details
• Source

Dexamethasone Solution and Dexamethasone in Mucolox™

• Sponsor: University of California, San Francisco
• Goal: The primary objective of this study is to determine the clinical efficacy and tolerability of compound dexamethasone at 0.5 mg/5 mL in Mucolox™ for the treatment of Oral Inflammatory Ulcerative Diseases as measured by a reduction in oral symptoms between patients treated with compounded dexamethasone 0.5mg/5ml solution in Mucolox™ (group A) and patients treated with topical commercial dexamethasone 0.5mg/5ml solution only (group B) and mucosa, leading to improved clinical outcomes due to the need for less frequent application.
• Interventions: Dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
• Primary Outcome Measure: Mean change from baseline in oral pain scores on the visual analog scale (VAS) at four weeks.
• Time Frame: Four weeks.
• Study Details
• Source

Ixekizumab in the Treatment of Bullous Pemphigoid

• Sponsor: Mayo Clinic
• Goal: The purpose of this study is to determine the effect of Ixekizumab on BP patients.
• Interventions: Ixekizumab
• Primary Outcome Measure: Cessation of blister formation.
• Time Frame: Up to 12 weeks.
• Study Details
• Source

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

• Sponsor: Alexion Pharmaceuticals, Inc.
• Goal: This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
• Interventions: Bertilimumab
• Primary Outcome Measures: Number of participants with anti-drug antibodies; Number of participants with treatment emergent adverse events (TEAEs).
• Time Frames: Baseline up to one year; Baseline up to one year.
• Study Details
• Source

Related Clinical Guideline:

• Management of Bullous Pemphigoid
  • European Academy of Dermatology and Venereology (EADV), June 2022

Sign up for alerts and stay informed on the latest published guidelines.